Andy Luman
Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Sumatera Utara, Medan – Indonesia

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Peran Inhibitor Sodium Glucose Co-transporter 2 (SGLT2) pada Terapi Diabetes Melitus Andy Luman
Cermin Dunia Kedokteran Vol 42, No 7 (2015): Stem Cell
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v42i7.985

Abstract

Inhibitor sodium glucose co-transporter 2 (SGLT2) merupakan suatu jenis obat antidiabetik dengan mekanisme kerja unik, yaitu menghambat secara spesifik SGLT2, suatu sistem transpor predominan reabsorpsi glukosa dari filtrasi glomerulus, sehingga penghambatan SGLT2 menurunkan reabsorpsi glukosa dari urin dan selanjutnya akan menurunkan kadar gula darah pada pasien diabetes.Inhibitor of sodium glucose co-transporter 2 (SGLT2) is a type of antidiabetic drug with a unique mechanism of action, which specifically inhibits SGLT2, a predominant transport system of glucose reabsorption from glomerular filtration, thus lowering the SGLT2 inhibition of glucose reabsorption from urine that can lower blood glucose levels in diabetic patients.
Statin-induced Diabetes Andy Luman
Cermin Dunia Kedokteran Vol 41, No 4 (2014): Dermatologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v41i4.1144

Abstract

Statin merupakan penghambat HMG-CoA reduktase yang berperan penting dalam penanganan dislipidemia. Penggunaan statin dikaitkan dengan peningkatan risiko diabetes, yang berhubungan dengan jenis (hidrofilik/ lipofilik), dosis, dan karakteristik klinis populasi. Penggunaan statin perlu diperhatikan dan pada populasi risiko kardiovaskular rendah perlu pemantauan teratur kadar glukosa darah.Statin is a HMG-CoA reductase inhibitor with important role in dyslipidemia management. Statin use is correlated with diabetes risk increase, associated with type (hydrophilic/lipophilic), dose, and clinical characteristics of population. The use of statins in population with low cardiovascular risk needs regular blood glucose monitoring.